Does a pre-submission meeting with FDA guarantee clearance?

No. A Pre-Sub meeting provides FDA's written feedback on your questions, which can include feedback on your predicate selection, testing plan, or clinical study design. It is FDA's assessment at that point in time, based on the information provided. It is not a commitment to clear, approve, or authorize the device. Representing a Pre-Sub response to investors as anything stronger than feedback would be inaccurate.

What is the difference between "cleared" and "approved" in FDA terms?

"Cleared" (or "510(k) cleared") means the FDA issued a substantial equivalence determination through the 510(k) premarket notification process. The FDA determined the device is at least as safe and effective as a legally marketed predicate device. "Approved" means the FDA issued an approval through the Premarket Approval (PMA) process, following an independent determination that the device is safe and effective based on valid scientific evidence. These are distinct regulatory outcomes from distinct pathways. Using "approved" for a cleared device constitutes misbranding under 21 CFR 807.97.

How long does FDA 510(k) review take?

FDA's MDUFA V Total Time to Decision goal is 112 calendar days for fiscal years 2025 through 2027, and actual times vary by device category, submission complexity, and whether FDA issues a request for additional information. FDA publishes annual 510(k) performance reports at https://www.fda.gov/medical-devices/510k-clearances/510k-performance-reports that include median total time from receipt to decision. These reports are the primary source for timeline expectations; general estimates may not reflect current FDA performance.

What is a request for additional information (AI) and how does it affect fundraising?

When FDA reviewers identify deficiencies in a 510(k) submission that are not sufficient to warrant a not-substantially-equivalent (NSE) determination, they may issue a request for additional information (sometimes called an "AI letter" or "additional information request"). This suspends the FDA review clock and requires the company to provide supplemental information. Responding to an AI letter typically takes two to six months, extending the overall clearance timeline. Founders should model for at least one AI response cycle in their runway planning and disclose this risk to investors.

Should I pursue IDE for a Class II device?

Most Class II devices do not require an IDE because they can demonstrate substantial equivalence through bench testing, animal study data, or previously published clinical literature. IDE is generally required for Class II devices that need clinical data that cannot be obtained from the existing literature or bench testing, or for devices with a novel mechanism of action where FDA requests clinical evidence before clearance. Your regulatory counsel can advise on whether your specific device will need clinical data and whether an IDE will be required to obtain it.

How FDA Regulatory Milestones Drive Medical Device Fundraising

Direct answer: FDA regulatory milestones are not just legal requirements: they are the primary de-risking events that unlock each stage of medical device fundraising. A completed pre-submission meeting reduces regulatory strategy risk. 510(k) clearance eliminates regulatory risk for Class II devices. An approved IDE unlocks pivotal trial funding for Class III devices. PMA approval opens the institutional and strategic growth capital markets. Investors who back medical devices price rounds around where a company sits in this regulatory sequence, because each milestone removes a specific category of risk that the prior round was carrying. (As of July 2026.)

Most medical device founders understand that FDA clearance matters for commercialization. Fewer understand how specifically FDA milestones map to investor psychology and fundraising readiness. This article makes that map explicit.

The Regulatory Timeline Is the Business Timeline

For a software company, the business timeline is customer acquisition: users, revenue, retention. For a medical device company, the business timeline is the FDA regulatory sequence. The reason: a device cannot be legally marketed in the United States without the appropriate regulatory authorization, and every commercial plan is conditional on that authorization arriving.

Investors in medtech understand this. When they evaluate a device company, they are evaluating the probability that the regulatory authorization arrives, when it arrives, and what happens to commercial traction after it arrives. Their capital is priced around that probability distribution.

This means that every major FDA regulatory event is simultaneously a regulatory event and a financial event. The milestones below trace that dual nature.

Milestone 1: Classification Determination

What it is. FDA device classification defines which regulatory pathway your device must follow. Class I devices (low risk) are mostly exempt from 510(k). Class II devices (moderate risk) typically require 510(k) clearance or De Novo authorization. Class III devices (high risk) require PMA approval.

Classification can be confirmed through the FDA product classification database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm) or, for novel devices without a clear classification, through a formal classification determination request to FDA.

What it means for fundraising. A device that founders believe is Class II but might be reclassified to Class III carries significantly higher capital requirements and timeline risk. Investors who discover this ambiguity in diligence will either reprice the round to reflect Class III risk or decline to invest until classification is confirmed. Knowing your device class with certainty, not assumption, before raising is foundational to a credible pitch.

Milestone 2: Pre-Submission Meeting (Q-Sub)

What it is. The FDA's Pre-Submission (Q-Sub) program allows device companies to request written feedback from FDA on specific questions before submitting a formal application (https://www.fda.gov/medical-devices/how-study-and-market-your-device/request-feedback-and-meetings-device-questions-q-sub-program). Pre-Sub meetings are most commonly used to confirm 510(k) predicate selection, validate the testing standard plan for a 510(k), or discuss clinical study design for IDE or PMA applications.

What it means for fundraising. A completed Pre-Sub meeting with written FDA feedback that validates your regulatory strategy is a meaningful de-risking event. It demonstrates that FDA has reviewed your approach, that you engaged the agency rather than hoping your assumptions were correct, and that any major strategic risk has been identified in time to address it. Institutional seed investors and some Series A investors will ask specifically whether you have engaged FDA in a Pre-Sub, and the absence of a Pre-Sub for a device that has been in development for more than twelve to eighteen months raises questions.

The FDA's response to a Pre-Sub does not guarantee clearance or approval. It is FDA's feedback, not a commitment. Representing FDA's Pre-Sub response as anything stronger than feedback to investors is inaccurate and could be characterized as misleading.

Milestone 3: Investigational Device Exemption (IDE) Approval

What it is. For Class III devices and some Class II devices that require clinical data beyond what bench testing can provide, an IDE allows the device to be used in a clinical study on human subjects. The IDE application describes the device, the study design, the risk analysis, and the informed consent process (https://www.fda.gov/medical-devices/how-study-and-market-your-device/investigational-device-exemption-ide).

FDA approves IDE applications after reviewing the study protocol and the risk justification for exposing human subjects to the device. An approved IDE means FDA has found the study design acceptable and the risk level justifiable.

What it means for fundraising. For PMA-pathway companies, IDE approval is often the key Series A gating milestone. It demonstrates that FDA has reviewed the study plan and found it acceptable. It also means the most capital-intensive phase of development, the pivotal clinical trial, can now proceed. Investors funding the pivotal trial are buying the clinical evidence that will form the core of the PMA application. An IDE approval also implies that FDA has already engaged meaningfully with the device and has not raised fundamental safety concerns.

Milestone 4: 510(k) Submission and Acceptance

What it is. A 510(k) submission is the formal premarket notification submitted to FDA demonstrating that a Class II device is substantially equivalent to a legally marketed predicate device (https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k). FDA's acceptance review confirms that the submission is substantively complete.

FDA measures 510(k) performance using decision time metrics it publishes in annual performance reports (https://www.fda.gov/medical-devices/510k-clearances/510k-performance-reports). Under MDUFA V, FDA's Total Time to Decision goal for 510(k)s is 112 calendar days for fiscal years 2025 through 2027; actual elapsed time varies significantly by device category and submission complexity, and FDA's published 510(k) performance reports are the authoritative source for current medians.

What it means for fundraising. A 510(k) submission that has been accepted removes the risk that the submission had basic deficiencies. For some investors, an accepted submission is a sufficient milestone for an interim bridge to keep the company funded while awaiting the clearance decision. For others, clearance itself is the required milestone. The submission does not guarantee clearance: FDA may issue a request for additional information (AI) or an interactive review request, which extends the clock. Modeling for this possibility in runway planning is important.

Milestone 5: 510(k) Clearance

What it is. Receiving a substantial equivalence determination from FDA means the device is cleared for commercial marketing with the cleared intended use. The clearance letter specifies the intended use and indications for use. Marketing claims must be consistent with the cleared intended use.

What it means for fundraising. 510(k) clearance is the single largest de-risking event in the life of most Class II medical device companies. It eliminates regulatory risk, which investors had been pricing. Companies that clear FDA almost universally raise their next round at a step-up in valuation, because the risk profile has changed materially. Post-clearance, the investor's primary questions shift to commercial execution, reimbursement, and adoption curve.

Post-clearance is also when marketing and commercial infrastructure need to be in place and ready to activate. A company that clears FDA with no commercial team, no reimbursement analysis, and no market-facing content will lose months to setup that well-prepared companies have already completed. Building those elements during the regulatory review period, not after clearance, is the standard practice for capital-efficient commercialization.

Milestone 6: De Novo Authorization

What it is. The De Novo classification request pathway applies to novel, low-to-moderate-risk devices that have no predicate device and therefore cannot use the 510(k) pathway. FDA issues a De Novo authorization (also called a De Novo classification order), not a clearance, when a De Novo is granted (https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request).

What it means for fundraising and marketing. From an investor and commercial perspective, De Novo authorization is functionally equivalent to 510(k) clearance in terms of risk removal. However, the correct marketing language is "De Novo granted" or "De Novo authorized," not "cleared." Using "cleared" for a De Novo device is the same category of regulatory language error as using "approved" for a 510(k) device. Investors who understand the regulatory vocabulary will notice this distinction.

De Novo authorization also creates the first predicate for the new device category, meaning subsequent devices can pursue 510(k) clearance using your De Novo device as a predicate. This creates a first-mover IP advantage in category creation, which is a commercial and competitive argument that sophisticated medtech investors understand.

Milestone 7: PMA Approval

What it is. Premarket Approval (PMA) is required for Class III devices. The PMA pathway requires independent FDA determination that the device is safe and effective, based on valid scientific evidence, typically including a randomized controlled pivotal clinical trial. The PMA approval order specifies the indication for use and any conditions of approval (https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma).

What it means for fundraising. PMA approval is typically achieved after a decade or more of development, multiple clinical studies, and $50 million to several hundred million in invested capital. Companies reaching PMA approval typically have institutional investors, corporate VC, and in many cases strategic partners already involved. Post-PMA raises are often growth equity rounds focused on commercial scale or IPO preparation.

The marketing implication is critical: PMA approval is the only pathway that allows the use of "FDA approved" in marketing. Using "FDA approved" for a 510(k) cleared or De Novo authorized device is misbranding under 21 CFR 807.97 (https://www.law.cornell.edu/cfr/text/21/807.97). Using it accurately for a PMA-approved device is correct and should be used consistently in all marketing materials.

The Investor's Regulatory Checklist

Experienced medtech investors run a rapid regulatory check during initial due diligence. The items they look for:

Is the device class confirmed, or is it assumed?
Has the founder identified the correct pathway (510(k), De Novo, PMA)?
For 510(k), has a predicate device been identified and the substantial equivalence argument been structured?
Has a pre-submission meeting been completed or scheduled?
Is qualified regulatory counsel engaged?
Does the marketing vocabulary match the regulatory status (cleared vs. approved vs. De Novo)?
What does the regulatory affairs infrastructure look like post-clearance?

A company that answers all seven questions well is demonstrably more investor-ready than one that has not worked through them. The first place an investor sees the answer to question six is your website.

Marketing Readiness at Each FDA Milestone

Each FDA milestone changes what you can say in marketing. Building your content calendar and website around the regulatory sequence, not just the product feature set, keeps your marketing accurate and avoids the misbranding risk that comes with premature commercial claims.

Before clearance: You can describe what your device is designed to do, the clinical problem it addresses, and your regulatory pathway. You cannot claim FDA authorization you have not received.

At clearance: You can say "FDA cleared" (for 510(k)) with the cleared intended use. Your marketing materials should be updated immediately at clearance to reflect cleared status accurately.

At De Novo: "De Novo granted" or "De Novo authorized" is the correct claim.

At PMA approval: "FDA approved" is correct and should be used consistently.

Building these content updates in advance so they deploy the day authorization arrives, rather than weeks later, is part of a well-managed commercial launch. Buzzbox Media works exclusively with medical device companies and has helped founders navigate the transition from pre-clearance to post-clearance marketing over 15 years of practice. If you want to build marketing that is regulatory-accurate, investor-ready, and commercially ready at the moment clearance arrives, a 30-minute call is a good place to start. Book at https://www.buzzboxmedia.com/book.